CymaBay Therapeutics, Inc. (CBAY) Stock Split, History Data
Working capital analysis
In terms of working capital, CymaBay Therapeutics, Inc. maintains a healthy position.
The total current assets of the company are valued at $403802000.
This represents a growth rate of 192.455% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $206535000, exhibiting a growth rate of 917.865% year-on-year.
On the liabilities side, the company's current liabilities total $36843000.
This reflects a growth rate of 138.605% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
206.53
20.29
125.81
28.19
24.87
48.99
Receavebles
0.00
0.00
0.00
0.28
0.69
0.00
Inventory
0.00
0.00
0.00
0.00
0.00
0.00
Other
9.55
2.59
4.56
4.99
11.29
0.30
Total Current Assets
403.80
138.07
191.10
151.59
202.92
181.56
Acc Payable
3.83
1.10
2.73
0.23
2.50
1.97
Short Term Debt
10.01
0.66
0.57
0.48
0.41
0.00
Other Current Liab
21.32
13.68
15.07
9.14
14.73
12.44
Current Liabilities
36.84
15.44
18.37
9.86
17.64
14.41
Capital Structure
When examining the capital structure of CymaBay Therapeutics, Inc., it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $434686000.
When juxtaposed with the previous year, this marks a growth rate of 206.436%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $142430000.
Compared to the prior year, this reflects a growth rate of 34.752%.
The long-term debt forms a sizable part of these liabilities, coming in at $99172000.
Over the last year, the long-term debt has grown by 9.877%.
On the asset side, the cash and equivalent reserves are worth $206535000.
The year-on-year growth of these reserves is 917.865%.
The company's common stock, another important asset, holds a value of $11000, growing at a rate of 37.500% from the previous year.
Finally, the company's retained earnings stand at $-978227000, marking a growth rate of 12.072% year-over-year.
These earnings represent the profits that CymaBay Therapeutics, Inc. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$434.69
Total liabilities
$142,430,000.00
Long term debt
$99.17
Cash and eqv
$206,535,000.00
Goodwill
$0.00
Retained earnings
-$978,227,000.00
Common stock
$0.00
Enterprise Value
-$40.30
Net earnings per share (EPS)
CymaBay Therapeutics, Inc. has an EPS of $-1.06, which signifies the profit allocated per share of common stock. With a growth rate of 27.541% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
